Trends in Immunotherapy

Case Report

Successful combined treatment with omalizumab and tocilizumab in a case of chronic spontaneous urticaria and rheumatoid arthritis: A case report and literature review

Downloads

https://doi.org/10.24294/ti.v6.i2.1443
Takeuchi, N., Yamanishi, A., Kumagai, Y., & Yokoyama, T. (2022). Successful combined treatment with omalizumab and tocilizumab in a case of chronic spontaneous urticaria and rheumatoid arthritis: A case report and literature review. Trends in Immunotherapy, 6(2). https://doi.org/10.24294/ti.v6.i2.1443
Volume 6 Issue 2 (2022)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Nao Takeuchi Department of Dermatology, Shizuoka City Shimizu Hospital
  • Ayumi Yamanishi Department of Dermatology, Shizuoka City Shimizu Hospital, Shizuoka 424-8636, Japan
  • Yoshiko Kumagai Department of Dermatology, Shizuoka City Shimizu Hospital, Shizuoka 424-8636, Japan
  • Tomoaki Yokoyama
    Department of Dermatology, Shizuoka City Shimizu Hospital, Shizuoka 424-8636, Japan

Omalizumab is a recombinant humanized monoclonal anti-IgE antibody used to treat uncontrolled chronic spontaneous urticaria (CSU). Sometimes patients with CSU also have other autoimmune conditions. Recent studies have demonstrated the safety and efficacy of a combination treatment with omalizumab and other biologics. Here, we report the first successful treatment with omalizumab for CSU and tocilizumab for rheumatoid arthritis. Since omalizumab is unlikely to cause severe immunosuppression, it may be a treatment option for CSU, even in patients treated with other biologics.

Keywords:

Chronic Spontaneous Urticaria Omalizumab Rheumatoid Arthritis Tocilizumab Anti-IL-6 Receptor Antibody

References

  1. Diluvio L, Vollono L, Zangrilli A, et al. Omalizumab and adalimumab: A winning couple. Immunoltherapy 2020; 12(8): 1287–1292. doi: 10.2217/imt-2020-0203
  2. Fougerousse AC, Becherel PA, Pallure V, et al. Combining omalizumab with another biotherapy. Acta Dermto-Venereologica 2019; 99(4): 448–449. doi: 10.2340/00015555-3140
  3. Ghazanfar MN, Thomsen SF. Combined treatment with omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis. Journal of Dermatological Treatment 2019; 30(4): 387–388. doi: 10.1080/09546634.2018.1515465
  4. Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. Journal of Allergy and Clinical Immunology 2014; 133(5): 1365–1372. doi: 10.1016/j.jaci.2013.12.1076
  5. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Annals of the Rheumatic Diseases 2007; 66(2): 228–234. doi: 10.1136/ard.2006.055111
  6. Rubini NPM, Ensina LFC, Silva EMK, et al. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis. Allergologia et Immunopatologia 2019; 47: 515–522. doi: 10.1016/j.aller.2019.05.003
  7. Diluvio L, Pensa C, Piccolo A, et al. Tildrakizumab and omalizumab: An interlocking therapy for autoimmune conditions. Journal of Clinical Images and Medical Case Reports 2021; 2(4): 1251. doi: 10.1111/dth.15359